Epiomic Epidemiology Series: Ovarian Cancer Forecast in 17 Major Markets 2015-2025

September 2015 | 50 pages | ID: E799F29FA4EEN
Black Swan Analysis limited

Abstracts

Ovarian Cancer begins in the ovaries, resulting from abnormal cells that have the ability to spread to other parts of the reproductive system and, in advanced stages, other parts of the body. The cause for Ovarian Cancer is not currently known, most DNA mutations for ovarian cancer are acquired genetic changes, however a link still has not yet been found to any environmental factors that may cause the mutation. This report provides the current incidence population for Ovarian Cancer across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Australia, Canada, Mexico, Turkey, South Africa, Saudi Arabia, Argentina and Russia) split by gender and 5-year age cohort. Along with the current incidence, the report provides an overview of the stages, grades and associated Charlson Co-morbidity scoring of Ovarian Cancer. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Ovarian Cancer have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Ovarian Cancer include:

• Diabetes
• Myocardial Infarct
• Mild Liver Disease
• Congestive Heart Failure
• Dementia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Ovarian Cancer’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Ovarian Cancer and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Ovarian Cancer’s prevalent population.
• Identify sub-populations within Ovarian Cancer which require treatment.
• Gain an understanding of the specific markets that have the largest number of Ovarian Cancer patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis &Clinical Course
Key Co-morbid Conditions Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Ovarian Cancer Incidence
Stages and Grading of Ovarian Cancer
  FIGO Staging of Ovarian Cancer
  Charlson Co-Morbidity Index and Ovarian Cancer
  Histopathology of Tumour Cells in Ovarian Cancer
Abbreviations and Acronyms used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Figures

LIST OF FIGURES

Ovarian Cancer Incidence Rates for 2015

List Of Tables

LIST OF TABLES

AJCC Tumour Grading Classification for Ovarian Cancer
FIGO Stage Descriptors of Ovarian Cancer
Charleston Co-morbidity Scoring Classification of Ovarian Cancer
Incidence of Ovarian Cancer, females (000s)
AJCC Stage at diagnosis for Ovarian cancer patients, females (000s)
FIGO staging in Ovarian Cancer patients, females (000s)
Stage I FIGO subtypes in Ovarian Cancer patients, females (000s)
Stage II FIGO subtypes in Ovarian Cancer patients, females (000s)
Stage III FIGO subtypes in Ovarian Cancer patients, females (000s)
Charleston Co-morbidity Scores for Ovarian Cancer patients, females (000s)
Major histopathological type in Ovarian Cancer patients, females (000s)
Adenocarcinoma subtypes in Ovarian Cancer patients, females (000s)
Abbreviations and Acronyms used in the Report
USA Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
France Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
Germany Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
Italy Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
Spain Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
United Kingdom Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
Brazil Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
Japan Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
India Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
Australia Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
Canada Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
Mexico Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
Turkey Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
South Africa Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
Saudi Arabia Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
Argentina Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)
Russia Incidence of Ovarian Cancer by 5-yr age cohort, females (000s)